Drug Interaction and Allergy Checking Clinicians Trust

Most knowledge bases ship with three to five interaction severity levels, and most hospitals deploy all of them interruptively at go-live. That is the single decision that creates alert fatigue. The tiers should map to distinct interface behaviours, not to distinct wordings of the same modal dialogue.

A workable mapping treats only contraindicated combinations as hard stops requiring a documented senior override; major interactions as interruptive alerts requiring a structured reason; moderate interactions as non-interruptive, passively displayed on the order screen where the prescriber can see them without acting; and minor interactions as suppressed entirely or available only on demand. The precise cut points are a local clinical decision, but the principle is not: if every tier interrupts, there are no tiers.

Route some alerts by role instead of suppressing them. An interaction that requires monitoring rather than a prescribing change is often better delivered to the verifying pharmacist or the nurse administering the dose than to the prescriber mid-order. HealUDoc can direct different alert categories to different points in the order-to-administration chain, which converts an interruption into a task assigned to whoever can act on it.

A true allergy is an immune-mediated reaction — anaphylaxis, urticaria, angioedema, bronchospasm — and it carries a genuine risk of a severe or fatal response on re-exposure. An intolerance is an adverse effect that is unpleasant but not immune-mediated: nausea with a macrolide, myalgia with a statin, dizziness with an opioid. Both belong in the record, but they should not generate the same alert, because treating them identically is how a patient loses access to an entire drug class over a single episode of nausea.

The clinical cost of conflating them is concrete and well recognised in the case of penicillin. A large proportion of patients labelled penicillin-allergic have a documented reaction that was not immune-mediated, or no documented reaction at all, and those labels drive them toward broader-spectrum alternatives with worse stewardship and sometimes worse outcomes. Capturing reaction type and severity at the point of entry is what makes de-labelling possible later.

The structured allergy entry should require the agent or class, the reaction described in coded terms, the reaction type — allergy, intolerance, or unknown — the severity, the approximate date, and who reported it. The reporter field earns its place: a reaction the patient recalls from childhood and a reaction observed by the treating team during this admission deserve different weight, and only the record can carry that difference forward.

Duplicate-therapy checking catches the patient who arrives on a home antihypertensive, is prescribed the same class under a different brand name during admission, and ends up on both. It works at two levels: exact-molecule duplication, which should almost always alert, and therapeutic-class duplication, which requires care. Class-level duplication is often deliberate — dual antiplatelet therapy, combination antihypertensives, multi-agent analgesia — so an unfiltered class check produces noise on the wards where it fires most.

The practical configuration is to alert on exact duplication universally, and to curate class-level duplication rules by exception: enable them for classes where duplication is genuinely dangerous and rarely intended, and disable them where combination therapy is standard. This takes a pharmacist a few afternoons and eliminates a large share of dismissed alerts.

Dose-range checking needs the patient's weight, age, renal function, and indication to be more than an approximate guess. Weight-based paediatric dosing and renally cleared agents are where the check earns its keep, and both fail silently if the weight field is stale or the creatinine is three admissions old. Before tuning dose-range alerts, audit whether the inputs they depend on are actually being captured — an alert computed from missing data is worse than no alert, because it teaches clinicians the check is unreliable.

Alert tuning has to be driven by data at the level of the individual rule, because aggregate override rates hide everything useful. Produce a monthly report listing each firing rule, its volume, its override rate, and the override reasons selected. Any rule overridden nearly every time it fires is a candidate for demotion, restriction to specific contexts, or removal — it is generating work and teaching dismissal without changing decisions.

Structured override reasons make this analysis possible, which is the main argument for requiring them on interruptive alerts. Give clinicians a short list — patient has tolerated previously, benefit outweighs risk, monitoring in place, not clinically significant here, will adjust dose — plus a free-text option, and keep the list short enough that the selection stays honest.

Set a review cadence and stick to it. A quarterly session where pharmacy and clinical informatics review the top twenty firing rules by volume, retire what is not earning attention, and document each change with its rationale will do more for medication safety than a knowledge-base upgrade. HealUDoc dashboards can surface firing volume and override rates by rule and by unit, but the demotion decision belongs to a clinical group with the authority to make it.

Interaction and allergy checking configuration needs a named owner and a change-control process, or it drifts. The usual arrangement places the rule set under the Pharmacy and Therapeutics Committee or a medication safety subgroup, with pharmacy informatics executing changes and a documented log of what changed, when, why, and who approved it. That log matters when an incident is reviewed months later and someone asks whether the alert was active at the time.

Knowledge-base vendor updates should be reviewed before deployment rather than applied silently. A content update can reclassify an interaction upward and produce a sudden alert surge on a ward that has changed nothing, and the ward will experience it as the system becoming unreliable.

Local additions deserve a higher bar than vendor content. A hospital-specific rule added after an incident is often the right response, but it should carry a review date, because rules added in the aftermath of an event tend to be broad and are rarely revisited once the event fades.

An alert that fires and is acted upon should leave a trace that the next clinician can find. If a prescriber overrode a major interaction because monitoring was in place, the monitoring plan should exist somewhere other than that clinician's memory — an order for the relevant level, a nursing instruction, a note in the plan. Otherwise the override reason was a formality and the risk it acknowledged is unmanaged.

Allergy entries need a maintenance path as much as an entry path. Build a de-labelling workflow: when a patient tolerates an agent they were labelled allergic to, the record should be updated with that evidence rather than accumulating an alert everyone ignores. Pharmacy-led review of allergy labels during admission, particularly antimicrobial labels, is one of the highest-yield uses of clinical pharmacist time available to most hospitals.

The end state to aim for is modest and achievable: alerts that fire rarely, that clinicians read, and whose disposition is visible in the record. Every configuration decision described here is in service of that, and none of them require a better knowledge base than the one most hospitals already own.